Showing 2 posts of 2 posts found.


Teva drops MS and Huntington’s disease drug laquinimod, leaving rights to Active Biotech

September 6, 2018
Medical Communications, Research and Development Active Biotech, Laquinimod, Teva, pharma

Israeli multinational Teva Pharmaceutical has decided to discontinue the development of laquinimod. As such, all rights for the orally administered …

Teva’s MS treatment disappoints

August 2, 2011
Research and Development, Sales and Marketing Laquinimod, MS, Teva

Teva and Active Biotech’s oral MS drug laquinimod has failed to meet its primary endpoint in a phase III trial. …

Latest content